CLINICAL TRIALS PROFILE FOR CLENBUTEROL

Clinical Trials for Clenbuterol

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00585546 ↗	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure	Terminated	Georgetown University	Phase 1	The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover sufficient heart function to allow the pump to be explanted. The study aims to avoid the need for transplantation in these patients by using standard heart failure medications to reduce the size of the left ventricle and then using the investigational drug, clenbuterol, to further improve left ventricular function.
NCT00585546 ↗	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure	Terminated	Montefiore Medical Center	Phase 1	The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover sufficient heart function to allow the pump to be explanted. The study aims to avoid the need for transplantation in these patients by using standard heart failure medications to reduce the size of the left ventricle and then using the investigational drug, clenbuterol, to further improve left ventricular function.
NCT00585546 ↗	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure	Terminated	Northwestern University	Phase 1	The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover sufficient heart function to allow the pump to be explanted. The study aims to avoid the need for transplantation in these patients by using standard heart failure medications to reduce the size of the left ventricle and then using the investigational drug, clenbuterol, to further improve left ventricular function.
NCT00585546 ↗	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure	Terminated	Ohio State University	Phase 1	The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover sufficient heart function to allow the pump to be explanted. The study aims to avoid the need for transplantation in these patients by using standard heart failure medications to reduce the size of the left ventricle and then using the investigational drug, clenbuterol, to further improve left ventricular function.
NCT00585546 ↗	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure	Terminated	Texas Heart Institute	Phase 1	The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover sufficient heart function to allow the pump to be explanted. The study aims to avoid the need for transplantation in these patients by using standard heart failure medications to reduce the size of the left ventricle and then using the investigational drug, clenbuterol, to further improve left ventricular function.
NCT00585546 ↗	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure	Terminated	Thoratec Corporation	Phase 1	The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover sufficient heart function to allow the pump to be explanted. The study aims to avoid the need for transplantation in these patients by using standard heart failure medications to reduce the size of the left ventricle and then using the investigational drug, clenbuterol, to further improve left ventricular function.

Clinical Trial Conditions for Clenbuterol

Condition Name

Condition Name for
Intervention	Trials
Healthy	2
Pompe Disease	1
Pompe Disease (Late-onset)	1
Skeletal Muscle Physiology	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Glycogen Storage Disease Type II	2
Infarction	1
Sclerosis	1
Heart Failure	1

Clinical Trial Locations for Clenbuterol

Trials by Country

Trials by Country for
Location	Trials
United States	10
Denmark	3
Netherlands	1

Trials by US State

Trials by US State for
Location	Trials
North Carolina	3
Texas	1
Pennsylvania	1
Ohio	1
New York	1

Clinical Trial Progress for Clenbuterol

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 2	4
Phase 1/Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	4
Not yet recruiting	2
Recruiting	2

Clinical Trial Sponsors for Clenbuterol

Sponsor Name

Sponsor Name for
Sponsor	Trials
Dwight Koeberl, M.D., Ph.D.	2
University of Copenhagen	2
Maastricht University	2

Sponsor Type

Sponsor Type for
Sponsor	Trials
Other	18
Industry	2